due to reduced SNpc dopaminergic (DA) neurons and exhaustion of corpus striatum DA. 4, 7, 8 At present, the primary therapeutic modalities for PD include dopaminergic medication (eg, levodopa [L-dopa] ) and surgical/electronic processes (eg, deep brain stimulation) through cell transplantation, while genetic and other therapies have been proposed. [9] [10] [11] However, the therapeutic outcomes are far away from satisfaction. Although drugs can improve patients' tremor and rigidity to some extent, they cannot inhibit the disease progression, or even induce severe complications like dyskinesia. Some neurotrophic factors, antiapoptotic agents, and immunosuppressants may prevent the neuron degeneration and necrosis and promote axon growth, 12 but they cannot resolve neural dysfunction due to DA deficiency caused by preexisted neuronal apoptosis/necrosis and therefore have no help to patients who already have had obvious clinical symptoms. Therefore, it is extremely important to explore new and better therapies for the prevention and treatment of PD.
Our recent studies show that activation of the delta-opioid receptor (DOR) is neuroprotective against hypoxic/ischemic injury. [13] [14] [15] This effect may be beneficial for the prevention of DA neuron damage in an aged brain with hypoxic/ischemic injury. More recently, we found direct evidence from in vitro PD models showing that DOR activation has an antiparkinsonism effect with a beneficial regulation of cellular and molecular signaling. 16 , 17 Mabrouk et al 18 have also found that DOR activation may be a useful target for symptomatic treatment of PD in humans 19 These data from our studies and those of others strongly suggest that DOR system may be a target for PD treatment.
This article reviews DOR-induced neuroprotection against PD and potential mechanisms underlying the DOR protection, which may provide a useful clue for in-depth research on better prevention and treatment of PD.
| PATHOG ENE S IS OF PD
The progression and development of scientific techniques and establishment of various models have become the driving force for the discovery of the etiology, pathogenic changes, and molecular mechanism of PD. 3, 7, 20 In general, the pathogenesis of PD is the joint result of environment, gene, and aging factors. At the cellular and molecular level, immunological abnormality, neuroinflammation, free radicals and oxidative stress, excitatory toxicity and calcium ion (Ca + ) toxicity, and other factors participate in the occurrence and development of PD. Motor symptoms of PD occur because of the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) that reduces dopaminergic transmitter levels in the nigrostriatal pathway, which then reduces the inhibitive function on the cholinergic system, thus triggering hypermyotonia, hypokinesia, and other symptoms. 1 The nonmotor symptoms of PD appear because DA of ventral tegmental area to marginal convolution of the midbrain is damaged, which results in autonomic nerve functional disorder and advanced neurological symptoms in partial patients. 21 
| Environmental insults
It is well known that 1-methyl-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP) causes typical PD symptoms in population. 22 Furthermore, there is evidence suggesting that the misregulation in microenvironmental iron metabolism, for example, ferric ion misregulation in the brain, is one of the initial causes for neuronal death in some neurodegenerative disorders such as PD. [24] [25] [26] [27] The iron regulatory hormone hepcidin decreases cell iron and ferritin contents and reduces cell injury, 25 while DOR activation significantly protected the SN cells from damage by iron deficiency. 
| Genetic defects
Genetic defects play important roles in the pathogenesis of PD.
Genetic missense mutation leads to primary structure change, ex- 
| DOR : A P OTENTIAL PROTEC TOR AG AIN S T PD
Opioid receptor agonists have been widely used in the clinic due to their strong analgesic effects. At present, there are three kinds of opioid receptors that have special pharmaceutical actions, namely MOR, KOR, and DOR. 50, 51 The three subtypes have different sequences in II and III extracellular regions as well as end terminals of N and C, indicating that they have different regulatory mechanisms. Enkephalin, an endogenous opioid receptor agonist, has a higher affinity for DOR compared to MOR and KOR. 52 DOR is highly distributed in the cortex and the basal ganglia.
53-55
Pharmaceutical experiments have shown that DOR has two subtypes, δ 1 (δ nex ) and δ 2 (δ ex ). 56 Both δ 1 and δ 2 receptors have relatively selective agonists, and their actions could be inhibited by their antagonists. 57 However, there has been no evidence for two separate DOR genes. In mice with gene deletions of DOR, DPDPE, an agonist for δ 1 , deltorphin, an agonist for δ 2 , and naltrindole, an antagonist for δ 1 and δ 2 had no δ 1 and δ 2 action in the animals, indicating that both δ 1 and δ 2 are coded by a single DOR gene. 58 Delta-opioid receptors neural functions other than pain modulation have not been well studied in the past. 52 In the past decade, we have conducted serial studies to explore DOR functions. One of the important findings is DOR neuroprotection, especially in hypoxic/ ischemic/excitatory conditions. [13] [14] [15] In cultured cortical neurons, DOR activation significantly reduces glutamate-induced neurotoxicity 13 and attenuates hypoxic injury. 58 For in vivo hypoxic and ischemic models, DOR activation ameliorates hypoxic brain injury and decreases ischemic infarction. 59 The DOR protection is mediated by the regulation of ionic hemostasis 
| P OTENTIAL MECHANIS MS FOR DOR PROTEC TI ON AG AIN S T PD
The data from our studies and those of others have shown that DOR displays its antiparkinsonism effect at multiple levels.
| DOR-mediated regulation in the striatum
The changes in basal ganglia function caused by the cell loss of the substantia nigra reticulata directly lead to the development of the cardinal features of PD. 72 The basal ganglia are a group of interconnected subcortical nuclei that contains the subthalamic nucleus (STN), the substantia nigra (pars reticulate and pars compacta, SNr and SNc), suboptimal globus pallidus internus (GPi) in primates, or its homolog in cats and rodents, the GPe, the globus pallidus (internal and external segments), and the striatum (caudate nucleus and putamen). 
| DOR-induced upregulation of PINK1 and downregulation of caspase 3
PINK1 is an important gene that was initially discovered to be mutated in early-onset parkinsonism. 81 Normal PINK1 expres- DOR activation with UFP-512 in hypoxic conditions. H + N: DOR inhibition with naltrindole in hypoxic conditions. **P < 0.01 vs. control. #P < 0.05, ##P < 0.01 vs H. Note that the level of cleaved caspase 3 increased and the level of procaspase 3 decreased after 48 h exposure to hypoxia. DOR activation with UFP-512 significantly attenuated the expression level of cleaved caspase 3, whereas naltrindole led to an increase in the level of cleaved caspase 3, and a decrease in that of inactivated caspase 3. Cited from Xu et al dysfunction, oxidative stress, and cell apoptosis. 84 However, pathogenic mutations of PINK1 in PD lead to a loss of function of the PINK1 molecule, 85 leading to reduced mitochondrial membrane potential, increased oxidative stress, and decreased ATP synthesis. Consequently, this induces the accumulation of damaged mitochondria in DA neurons due to defective mitophagy 86, 87 and then the release of apoptotic signals. 88 Like most cells which undergo cell apoptosis, the death of the midbrain dopaminergic neurons in PD is caspase-dependent. 89 Once the initiator caspases are activated by apoptotic signals, a chain reaction occurs, thus activating other executioner caspases, leading to cell death. 90 As DOR plays a critical role in neuroprotection under hypoxic insults and hypoxic/ ischemic stress is one of the underlying causes of PD, 40 we therefore studied whether DOR activation affects PINK1 and caspases in parkinsonism condition.
MPP + (1-methyl-4-phenyl-pyridinium ion) is a neurotoxic agent that had been widely used in cell and animal models by damaging the dopaminergic neurons in the substantia nigra to minimize the PD conditions. 91 We therefore applied it to PC-12 cells to establish in vitro PD models. We also applied hypoxia to the cell model with or without MPP + as hypoxia is potentially a pathologic factor for the genesis of PD. We found that both MPP + stress and prolonged hypoxia caused severe cell injury. MPP + stress reduced PINK1 expression in a dose-dependent manner, and the higher the MPP+ concentration was, the lower the PINK1 expression (Figure 1 ).
Prolonged hypoxia also decreased PINK1 expression. In contrast, 
| DOR attenuation of ɑ-synuclein dysregulation via CREB phosphorylation
The aberrant aggregation of ɑ-synuclein into oligomers induces neurotoxicity that contributes to the pathogenesis of PD and other neurodegenerative diseases. 92, 93 Although the function of ɑ-synuclein under normal conditions is poorly understood, it is highly expressed in the neurons as well as other tissues such as hematopoietic cells. A point mutation in the ɑ-synuclein gene has been found as the cause of a familial form of PD that is inherited as a dominant trait. 94 This has led to extensive characterization of altered ɑ-synuclein structure in the sporadic form of PD along with other neurodegenerative disorders. It is well believed that prefibrillar oligomers and protofibrils are the pathognomonic of PD rather than mature ɑ-synuclein fibrils. 92, 93 We therefore studied whether DOR acts on α-synuclein expression and oligomer formation in the cell PD model. Similar to the above studies, we applied MPP and/or hypoxia on HEK293 cells to mimic parkinsonism condition in vitro. We found that in normoxia, MPP + increased ɑ-synuclein expression and the formation of ɑ-synuclein oligomers and caused cytotoxic injury. Prolonged hypoxia (1% oxygen for 48 hours) or severe hypoxia (0.5% oxygen for 24 hours) also induced ɑ-synuclein overexpression and its oligomer formation with cell injury. However, hypoxia at 1% oxygen for 24 hours, though increasing ɑ-synuclein expression, did not cause ɑ-synuclein oligomer formation and cell injury. The activation of DOR markedly attenuated hypoxic cell injury and ɑ-synuclein overexpression. This DOR effect was greatly attenuated by DOR inhibition with naltrindole or DOR "knock-down" by siRNA. DOR activation also reduced MPP + -induced ɑ-synuclein overexpression, which was also reversed by DOR antagonism with naltrindole ( Figures 5 and 6 ).
To deeply elucidate the mechanism for the DOR-mediated cytoprotection, we measured hypoxia/MPP+ induced changes in No significant changes in the total amount of CREB levels were found in all these conditions. Furthermore, we found that the activation of DOR increased CREB phosphorylation and prevented the collapse of mitochondrial membrane potential (△ψm). These results suggest that DOR activation is able to attenuate ɑ-synuclein overexpression/aggregation via a CREB pathway.
This study concluded that DOR activation could reduce mitochondrial and brain cell injury by upregulating CREB phosphorylation, suggesting that DOR had potential protective mechanism against overexpression of ɑ-synuclein, oligomer formation, and cell injury caused by MPP + and/or hypoxia stress, and that DOR might be used as a potential therapeutic for PD-like conditions. However, more studies are required to elucidate the interaction between DOR and ions in PD. In addition, it is not well known how DOR interacts with the various genes and neurotransmitters such as GABA, glutamate, and dopamine in different regions of the PD brain.
| CON CLUS I ON S AND PER S PEC TIVE S
In summary, emerging evidence suggests that DOR is an important 
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